WHAT IS CLAIMED IS:

Claims 1-19. (Cancelled).

20. A method for treating a cytokine-mediated immune reaction in a patient in need thereof comprising, topically administering to said patient an effective amount of anti-cytokine $F(ab')_2$ antibody fragments.

21. The method of claim 20, wherein said cytokine-mediated immune reaction comprises a T cell-mediated inflammatory disease.

22. The method of claim 21, wherein said T cell-mediated inflammatory disease comprises psoriasis vulgaris.

23. The method of claim 20, wherein said cytokine-mediated immune reaction comprises chronic inflammatory disease.

24. The method of claim 20, wherein said cytokine-mediated immune reaction comprises acute inflammatory disease.

25. The method of claim 23, wherein said chronic inflammatory disease comprises rheumatoid arthritis.

26. The method of claim 23, wherein said chronic inflammatory disease comprises an ophthalmic inflammatory disorder.

27. The method of claim 24, wherein said acute inflammatory disease comprises an ophthalmic inflammatory disorder.

28. The method claim 26 or 27, wherein said ophthalmic inflammatory disorder is selected from the group consisting of: keratitis, uveitis, blepharitis, dry eye and inflammation related to infection.

29. The method of claim 20, wherein said cytokine-mediated immune reaction is acute inflammatory disease.

30. The method of claim 20, wherein said cytokine-mediated immune reaction comprises septic shock.

31. The method of claim 20, wherein said cytokine-mediated immune reaction comprises rejection of a prosthetic or tissue transplant.

32. The method of claim 31, wherein said tissue transplant rejection comprises acute corneal transplant rejection.

33. The method of any one of claims 20 to 32, wherein said anti-cytokine $F(ab')_2$ antibody fragments are applied in combination with a dermatologically or ophthalmically acceptable carrier.

34. The method of any one of claims 20 to 32, wherein said anti-cytokine $F(ab')_2$ antibody fragments are substantially free of albumin, whole antibodies, pyrogens and/or viruses.

35. The method of claim 34, wherein said anti-cytokine $F(ab')_2$ antibody fragments are administered in combination with a dermatologically or ophthalmically acceptable carrier.

36. The method of any one of claims 20 to 35, wherein said cytokine is alpha tumor necrosis factor (TNF-α)

37. The method of any one of claims 20 to 35, wherein said cytokine is beta tumor necrosis factor (TNF-β).

38. The method of any one of claims 20 to 35, wherein said cytokine is an interleukin.

39. The method of claim 38, wherein said interleukin is interleukin-1 (IL-1).

40. The method of claim 38, wherein said interleukin is interleukin-1 alpha (IL-1α).

41. The method of claim 38, wherein said interleukin is interleukin-1 beta (IL-1β).

AMENDED SHEET

PCT/IB 03/02971
IPEA/US 25 FEB 2005

42. The method of claim 38, wherein said interleukin is interleukin-2 (IL-2).

43. The method of claim 38, wherein said interleukin is interleukin-6 (IL-6).

44. The method of claim 38, wherein said interleukin is interleukin-12 (IL-12).

45. The method of any one of claims 20 to 35, wherein said cytokine is gamma interferon (IFN-γ).

46. The method of claim 33 or 35, wherein said ophthalmically acceptable carrier comprises one or more components, and wherein said components are selected from the group consisting of: sodium chloride, monobasic sodium phosphate, dibasic sodium phosphate, benzalkonium chloride, methylparaben, propylparaben, tween 80, sodium thiosulphate, sodium metabisulphite, cremophor EL, polyvinilic alcohol, citric acid, boric acid, sodium borate, sodium citrate, glycerine, sodium bisulfite, hydroxypropyl methylcellulose, ethylenediaminetetraacetic acid (EDTA), and reverse osmosis purified water.

47. The use of anti-cytokine $F(ab')_2$ antibody fragments for the manufacture of a medicament for the treatment of a cytokine-mediated immune reaction in a patient in need thereof, wherein said medicament is suitable for topical administration.

48. The use of claim 47, wherein said cytokine is TNF-α.

AMENDED SHEET

49. The use of claim 47, wherein said cytokine is TNF-β.

50. The use of claim 47, wherein said medicament is suitable for dermatological administration.

51. The use of claim 47, wherein said medicament is suitable for ophthalmic administration.

52. The use of claim 47, wherein said anti-cytokine $F(ab')_2$ antibody fragments are substantially free of albumin, whole antibodies, pyrogens and/or viruses.

53. The use of any one of claims 47 to 52, wherein said cytokine-mediated immune reaction comprises a T cell-mediated inflammatory disease.

54. The use of any one of claims 47 to 52, wherein said cytokine-mediated immune reaction comprises a chronic or acute inflammatory disease.

55. The use of claim 54, wherein said acute or chronic inflammatory disease comprises an ophthalmic inflammatory disorder.

56. The use of claim 55, wherein said ophthalmic inflammatory disorder is selected from the group consisting of: keratitis, uveitis, blepharitis, dry eye and inflammation related to infection.

57. The use of any one of claims 47 to 52, wherein said cytokine-mediated immune reaction comprises sepsis.

58. The use of any one of claims 47 to 52, wherein said cytokine-mediated immune reaction comprises septic shock.

59. The use of any one of claims 47 to 52, wherein said cytokine-mediated immune reaction comprises rheumatoid arthritis.

60. The use of any one of claims 47 to 52, wherein said cytokine-mediated immune reaction comprises rejection of a prosthetic or tissue transplant.

61. The use of claim 60, wherein said tissue transplant rejection is acute corneal transplant rejection.